1) In class we talked about the formation of VLDL(very low density lipoprotein)

Question

1) In class we talked about the formation of VLDL(very low density lipoprotein) lipoproteins in the liver.   The assembly of VLDL particles within the liver involves a protein called microsomal triglyceride transfer protein (MTP), which is essential for the assembly of apolipoprotein B (apo-B) containing lipoproteins. Known inhibition of MTP prevents hepatic VLDL secretion by preventing VLDL production. Given this effect, drugs targeting MTP are of interest as potential drugs for hyperlipidemia (a condition with elevated levels of lipid and/or lipoproteins).

Based on your understanding of relevant pathways involving VLDL, explain the basis of MTP inhibition as a hyperlipidemia drug. Would you expect LDL levels in the blood to increase or decrease?

Explanation / Answer

SOLUTION:

If MTP (microsomal triglyceride transfer protein) inhibition is used as a hyperlipidemia drug then LDL levels in the blood decrease

Explanation:

Hyperlipidemia is a condition in which increased the levels of lipids or fats in the blood and also increasing cholesterol and triglycerides level into the blood.

If MTP inhibition occurs as a hyperlipidemic drug or effect of hyperlipidemic drug then following situations occurs

1: Decrease low-density lipoprotein (LDL) cholesterol

LDL cholesterol is called bed cholesterol, due to this increases the risk of heart diseases.

2: Decrease the amount triglycerides

It is a fat which increases the risk of heart diseases.

     3: Increase high-density lipoprotein (HDL) cholesterol

      It is called good cholesterol which is protect heart from heart disease

Related Questions

Navigate

• Browse (All)
• Browse 1
• Subjects

Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.